ClinicalTrials.gg
CompletedNCT06651021Updated Jan 15, 2025

A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

A Phase 1 interventional study of balcinrenone/dapagliflozin in Healthy Volunteer, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is intended to evaluate the PK, safety, and tolerability of balcinrenone/dapagliflozin given as a single dose capsule to healthy Chinese participants.

Read the detailed description

This is a Phase I, open-label, single-arm, single dose PK study in healthy Chinese participants to be conducted at a single study centre in mainland China. In this study, approximately 10 participants (both females and males) will be assigned to the IMP. Each participant will receive a single dose of a capsule with balcinrenone/dapagliflozin 40 mg/10 mg on Day 1 under fasted condition. The study will comprise of the following:

  • A screening period
  • A treatment period
  • A follow-up visit At the discretion of the investigator, the participant may remain in the study center until the completion of the follow-up visit
02

Conditions studied

  • Healthy Volunteer

Keywords

  • Chinese Healthy Volunteer
  • Phase 1
  • Pharmacokinetics
  • Safety
  • Tolerability
  • balcinrenone/dapagliflozin
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age

  1. Participant aged 18 to 50 years.

    Type of Participant and Disease Characteristics

  2. Chinese participants who are healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.

    Weight

  3. Body weight within 50.0-100.0 kg and within the range 19.0-28.0 kg/m2 (inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. History of any disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the administration of IMP.
  4. Any clinically significant abnormal findings in vital signs, as judged by the investigator.
  5. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator.
  6. Any positive result on screening for serum or anti-hepatitis B core antibody, antibody, and antibody.
  7. Positive screen for drugs of abuse, alcohol or cotinine at screening or on admission to the study centre.
  8. Suspected or confirmed COVID-19 infection within the last 4 weeks prior to screening or admission. Or hospitalisation for COVID-19 within the last 12 weeks prior to screening or admission.
  9. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
  10. Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.
  11. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to balcinrenone or dapagliflozin.

    Prior/Concomitant Therapy

  12. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), hormone replacement therapy, herbal remedies, megadose vitamins and minerals within 14 days or 5 half-lives (whichever is longer) before the start of IMP, unless, in the opinion of the investigator, the medication will not interfere with the study.

    Prior/Concurrent another Clinical Study Experience

  13. Has received product within 3 months (or 5 half-lives, whichever is longer) of administration of study intervention in this study.

    Other Exclusions

  14. Involvement in the planning and/or conduct of this study.
  15. Judgment by the investigator that the participant should not participate in this study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  16. Previous enrolment in the present study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    balcinrenone/dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Drug: balcinrenone/dapagliflozin

Interventions

  • Drugbalcinrenone/dapagliflozin

    Drug pages: AZD9977 · Dapagliflozin

    Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition. Each participant will be involved in the study for up to 35 days.

06

What researchers measure

Primary outcomes

  1. AUCinf of AUCinf of balcinrenone/dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  2. AUClast of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  3. Cmax of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  4. C24h of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  5. tmax of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  6. t½λz of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  7. λz of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  8. CL/F of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  9. MRTinf of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

  10. Vz/F of balcinrenone /dapagliflozin

    To evaluate the PK of balcinrenone /dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: Day 1 to post dose 48 hours

Other outcomes

  1. Incidence of AEs and SAEs

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  2. Incidence of abnormal Supine blood pressure

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  3. Incidence of abnormal Supine Pulse

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  4. Height in centimeter

    This is related to Body Mass Index, To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  5. Weight in Kilograms

    This is related to Body Mass Index, To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  6. Incidence of abnormal clinical chemistry assessments:Glucose, HbA1c, Creatinine, , ALP, ALP, ALT, AST, total bilirubin, Potassium, Chloride, Bicarbonate, Calcium (total), magnesium, Phosphorous, Sodium, CK, eGFR, FSH, hCG

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  7. Incidence of abnormal urinalysis: Glucose, Haemoglobin, Protein/Albumin, hCG

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  8. Incidence of abnormal haematology assessments: Haematocrit, Hb, Platelet count, RBC, WBC

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  9. Incidence of abnormal of Electrocardiogram parameter: ECG mean heart rate

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  10. Incidence of abnormal of Electrocardiogram parameter: ECG Heart rhythm

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  11. Incidence of abnormal of Electrocardiogram parameter: ECG QRS duration, QT interval, QTc interval Fridericia

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  12. Incidence of abnormal physical examination: assessments of general appearance, respiratory, CV, abdomen, neurological systems, the skin, lymph nodes

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

  13. Incidence of abnormal physical examination: assessment of the presence and extent of peripheral (ankle/leg) oedema

    To assess the safety and tolerability of balcinrenone/dapagliflozin given as a single dose to healthy Chinese participants

    Time frame: From ICF throughout the treatment period and including the follow-up period (7 days post-dose)

07

Study locations

1 site
  • Research Site
    Chengdu, 610041, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Oct 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Oct 21, 2024
StartActual
Oct 21, 2024
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06651021
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Oct 21, 2024
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Last update
Jan 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD9977 · Dapagliflozin

Start the discussion